35 results
Page 2 of 2
424B5
3zwdt5xxd40
21 Feb 19
Prospectus supplement for primary offering
9:24pm
424B5
v0on55y
21 Feb 19
Prospectus supplement for primary offering
9:22pm
424B5
k6i2gx
19 Feb 19
Prospectus supplement for primary offering
4:06pm
424B5
pxvn6gn oie8xlonmvy
19 Feb 19
Prospectus supplement for primary offering
4:04pm
8-K
EX-99.1
80czg3
19 Feb 19
Results of Operations and Financial Condition
4:01pm
8-K
EX-99.1
e3spvtji k2ypol2z
7 Jan 19
Regulation FD Disclosure
6:31am
8-K
EX-99.1
5ntww6wf
6 Dec 18
Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
8:05am
8-K
EX-99.1
jzu8vc9 bgjysz37oti
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.2
l4lgc0b1
25 Oct 18
Regulation FD Disclosure
10:25am
8-K
EX-99.1
ngg4lauz5 nq2
6 Aug 18
Ovid Therapeutics Announces Positive Topline Data from Phase 2 STARS Trial of OV101 for the Treatment of Angelman Syndrome
7:16am
8-K
EX-99.1
9g76 kqpmaax
19 Jul 18
Other Events
6:59am
8-K
EX-99.1
6wgw5k3g
8 May 18
Results of Operations and Financial Condition
5:22pm
10-K
2773p
29 Mar 18
Annual report
12:00am